Skip to content

Rafael Holdings, Inc. RFL Warrants and Rights Outstanding

Warrants and Rights Outstanding at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA

Other financials

Income statement

See full
Revenue$179.0K-50.6%
Gross profit$131.0K-56.3%
Operating income-$6.9M-16.2%
Net income-$4.2M+11.6%
EPS (diluted)-$0.08+57.9%

Balance sheet

See full
Cash & equivalents$30.5M-19.6%
Total debt$21.9M+995%
Total equity$75.4M-6.4%
Total assets$92.0M-14.9%

Cash flow

See full
Operating cash flow-$7.3M-128%
CapEx$6.0K
Free cash flow-$7.3M-128%

Valuation

See full
Market cap$170.56M+189%
P/S174×+93.5×

Profitability

See full
Gross margin71.9%
Operating margin-3,717.2%+1,952pp
Net margin-2,117.2%-517pp
FCF margin-2,064.1%

Returns & leverage

See full
Return on equity-26.6%-0.8pp
Debt / equity0.3×+0.2×
Current ratio3.2×-0.7×

Where this comes from

Reported directly by Rafael Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ClassOfWarrantOrRightOutstanding.

The official record: Rafael Holdings, Inc.’s 10-Q, filed June 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rafael Holdings, Inc.'s warrants and rights outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rafael Holdings, Inc.'s warrants and rights outstanding?
Rafael Holdings, Inc. (RFL) reported warrants and rights outstanding of 645.2K in Q1 2026.
How has Rafael Holdings, Inc.'s warrants and rights outstanding changed year-over-year?
Rafael Holdings, Inc.'s warrants and rights outstanding decreased by 39.1% year-over-year, from 1.1M to 645.2K.
What does warrants and rights outstanding mean?
This represents the total value or quantity of derivative instruments issued by the company that grant holders the right to purchase equity at a specified price. These instruments represent potential future dilution to existing shareholders upon exercise. Tracking this metric is essential for understanding the company's capital structure and potential future equity issuance.